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Abstract
Whole genome amplification can faithfully amplify genomic DNA (gDNA) with minimal bias and substantial genome
coverage. Whole genome amplified DNA (wgaDNA) has been tested to be workable for high-throughput genotyping arrays.
However, issues about whether wgaDNA would decrease genotyping performance at increasing multiplexing levels and
whether the storage period of wgaDNA would reduce genotyping performance have not been examined. Using the
Sequenom MassARRAY iPLEX Gold assays, we investigated 174 single nucleotide polymorphisms for 3 groups of matched
samples: group 1 of 20 gDNA samples, group 2 of 20 freshly prepared wgaDNA samples, and group 3 of 20 stored wgaDNA
samples that had been kept frozen at270uC for 18 months. MassARRAY is a medium-throughput genotyping platform with
reaction chemistry different from those of high-throughput genotyping arrays. The results showed that genotyping
performance (efficiency and accuracy) of freshly prepared wgaDNA was similar to that of gDNA at various multiplexing
levels (17-plex, 21-plex, 28-plex and 36-plex) of the MassARRAY assays. However, compared with gDNA or freshly prepared
wgaDNA, stored wgaDNA was found to give diminished genotyping performance (efficiency and accuracy) due to
potentially inferior quality. Consequently, no matter whether gDNA or wgaDNA was used, better genotyping efficiency
would tend to have better genotyping accuracy.
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Introduction
With the availability of the complete sequence [1–3] and
haplotype map [4–6] of the human genome, paradigm of genetic
association studies has switched from candidate-gene design to
genomewide approach. Linkage studies have been proven to be a
successful strategy for Mendelian diseases with relatively low
prevalence, high penetrance and large effect size. Nevertheless,
efforts have been increasingly focused on common complex
diseases, which are more appropriately and effectively tackled by
association rather than linkage approach. With advancement in
technology, genotyping of thousands to even millions of single
nucleotide polymorphism (SNP) markers is now possible and
widely available. This popularizes the genomewide association
approach. No matter which approach, linkage vs association or
candidate-gene vs genomewide, is adopted, a large number of
genetic markers, most likely SNPs, have to be genotyped for a
large number of subjects. Subject recruitment is always a major
bottleneck for genetic studies. To recruit subjects for achieving
enough statistical power, this step may take years to accomplish.
The difficulty will be even greater for recruiting families.
One fundamental constraint on modern genetic studies is the
limited supply of precious samples – genomic DNA (gDNA)
extracted from blood in most cases. Despite the increasing level of
multiplexing in genotyping and relatively small amounts of DNA
required in most applications, the amount of gDNA extracted may
still be insufficient for extensive use. Epstein-Barr virus-trans-
formed cell lines have been used to provide unlimited amounts of
DNA, but this method is labor-intensive, expensive and inappli-
cable to existing DNA samples. Several methods of whole genome
amplification (WGA) [7] have also been developed to tackle this
major challenge: PCR-based strategies using random oligonucle-
otide primers [8] or degenerate oligonucleotide primers [9],
OmniPlex technology [10] and multiple displacement amplifica-
tion (MDA) [11]. MDA is the most reliable method to faithfully
amplify gDNA with minimal bias and substantial genome
coverage [7,12,13]. It can generate products with average size
.10 kb, and the relatively consistent product yield is less sensitive
to the amount of starting material [7,11]. Whole genome amplified
DNA (wgaDNA) from MDA methods can be used in a variety of
applications including high-throughput genotyping [7,14], e.g.,
Affymetrix array [15] and Illumina BeadArray [16]. In addition,
the starting DNA sample for WGA needs not to be fresh [17].
Such versatile applicability makes MDA the best and most popular
WGA method. However, to our knowledge, it is not yet known
whether wgaDNA samples would affect the overall performance
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with respect to multiplexing level (i.e. the complexity of assay), and
whether the genotyping performance of wgaDNA would be
affected by the period of storage.
This study is part of an on-going myopia genomics study. It
provides comparative information on freshly prepared wgaDNAs
and stored wgaDNAs (stored frozen for a period of time) against
their gDNA counterparts. It also allows evaluation of the
genotyping efficiency and accuracy for these three types of
samples genotyped using the MassARRAY Sequenom SNP
genotyping platform with iPLEX GOLD chemistry. Despite the
fact that testing wgaDNA with the MassARRAY platform has
been carried out before [17], the present study is the first one that
systematically investigates the genotyping performance of
wgaDNA with respect to the multiplexing level and the potential
effect of storage period on wgaDNA genotyped using the same
technology. Samples were amplified using MDA-based Genomi-
Phi V2 DNA Amplification Kit (GE Healthcare Life Sciences).
MDA-based kit was used because of the numerous merits of the
MDA method over others. Genotyping efficiency was assessed in
terms of genotype completion rates while genotyping accuracy was
evaluated based on genotype concordance rate between matched
pairs of wgaDNA and gDNA samples. The effect of storage period
on wgaDNA was also evaluated, and subgroup analysis stratified
by multiplexing group was used to study the correlation of
multiplexing level with wgaDNA usage.
Results
DNA quantification and quality control
gDNA samples were quantified using ultraviolet spectropho-
tometry and each sample had an initial concentration of
.100 ng/ml. They were diluted to 15 ng/ml with Tris-EDTA
(TE) solution. wgaDNA was amplified from 10 ng of gDNA
according to the manufacturer’s instruction. It has been found that
at least 10 ng of gDNA should be used for WGA [12,18]. The
yield of wgaDNA ranged from,10 mg to 20 mg – an increase of at
least 1000 times the starting amount of gDNA. They were diluted
to 15 ng/ml with TE. A single SNP that had been successfully
genotyped for gDNA samples by the method of restriction
fragment length polymorphism as part of our on-going myopia
genomics study was genotyped again for all wgaDNA samples by
the same method. Samples that failed this quality control step were
replaced. This served to ensure adequate quantity and good
quality of all wgaDNA samples.
Assessment of genotyping efficiency
We investigated the MassARRAY genotype data of 174 SNPs for
the 3 groups of matched samples: group 1 (20 gDNA samples),
group 2 (20 freshly prepared wgaDNA samples) and group 3 (20
stored wgaDNA samples that had been stored frozen at 270uC for
18 months). To be consistent and precise, we hereafter used the
term ‘‘stored wgaDNA’’ to refer specifically to wgaDNA that had
been stored frozen at270uC for 18 months, unless stated otherwise.
We used genotype completion rates to assess genotyping
efficiency. The mean genotype completion rates for groups 1 to
3 samples were 96.8%, 96.2% and 93.0%, respectively (Table 1).
Obviously, group 1 gDNA samples achieved the highest mean
genotype completion rate for the 174 SNPs genotyped and the
values were also the least dispersed with the lowest SD of 12.0%
(Figure 1).
Table 1. Summary of genotyping efficiency among sample groups stratified by multiplexing level.
Mean genotype completion rate (SD)
P value for pairwise comparison of mean
genotype completion rates (Group a vs b)e
Multiplexing level No. of SNPs Group 1a Group 2b Group 3c P valued 1 vs 2 1 vs 3 2 vs 3
All 174 96.8 (12.0) 96.2 (14.4) 93.0 (19.0) 0.002 0.431 1.73e-04 0.003
17-plex 17 99.1 (2.0) 99.4 (1.7) 93.8 (6.3) 1.12e-04 0.317 0.007 0.005
21-plex 21 95.7 (15.2) 94.8 (20.6) 91.0 (25.1) 0.186 0.655 0.161 0.096
28-plex 28 98.6 (2.3) 98.2 (2.8) 97.5 (5.0) 0.723 0.480 0.305 0.417
36-plex 108 96.2 (13.5) 95.4 (15.7) 92.2 (21.1) 0.269 0.557 0.036 0.211
aMean genotype completion rates were not significantly different (P= 0.197, Kruskal-Wallis test) across multiplexing levels. However, there was significant, albeit weak,
correlation between mean genotype completion rates and multiplexing levels (coefficient =20.163, P= 0.032).
bMean genotype completion rates were not significantly different (P= 0.168, Kruskal-Wallis test) across multiplexing levels. However, there was significant, albeit weak,
correlation between mean genotype completion rates and multiplexing levels (coefficient =20.155, P= 0.041).
cMean genotype completion rates was not significantly different (P= 0.078, Kruskal-Wallis test) across multiplexing levels. There was no significant correlation between
mean genotype completion rates and multiplexing levels either (coefficient = 0.045, P= 0.599).
dP values for comparison of mean genotype completion rates across three matched sample groups by Friedman test.
eP values for matched pairwise comparison of mean genotype completion rates by Wilcoxon signed rank test.
doi:10.1371/journal.pone.0026119.t001
Figure 1. Genotyping efficiency for different sample groups
based on 174 SNPs genotyped using MassARRAY assay.
doi:10.1371/journal.pone.0026119.g001
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To find out whether the use of wgaDNA samples and the
storage period of wgaDNA would reduce the genotyping
efficiency, mean genotype completion rates were compared among
these 3 sample groups (Table 1) and found to be significantly
different (P=0.002). As expected, pairwise comparison did not
show any significant difference in mean genotype completion rate
between groups 1 and 2 (P=0.431, Table 1). However, significant
differences were shown between groups 1 and 3 (P=1.73e-4) and
between groups 2 and 3 (P=0.003). This indicated that the storage
period of wgaDNA was likely to reduce the genotyping efficiency.
Stratified analyses were performed to investigate the potential
effect of using stored wgaDNA on the genotyping efficiency with
respect to multiplexing level in the MassARRAY assay. Again,
considering mean genotype completion rate across sample groups,
there were significant differences only at the 17-plex level
(P=1.12e-4; Table 1). On the other hand, within each sample
group, there was no significant difference in mean genotype
completion rates among four multiplexing levels (P=0.197, 0.168,
0.078 for groups 1 to 3 respectively; footnotes a to c, Table 1).
When genotype completion rates were compared across multi-
plexing levels (17-plex, 21-plex, 28-plex and 36-plex) for potential
correlation, significant albeit weak correlation could be detected for
groups 1 and 2 samples, but not group 3 samples.
For pairwise comparisons stratified by multiplexing level, the
most contrasting differences were detected between groups 1 and 3
samples although there were no significant differences at certain
multiplexing levels (all: 1.73e-04; 17-plex: P=0.007; 21-plex:
P=0.161; 28-plex: P=0.305; 36-plex: P=0.036; Table 1). Similar
results were detected between groups 2 and 3 samples (all: 0.003;
17-plex: P=0.005; 21-plex: P=0.096; 28-plex: P=0.417; 36-plex:
P=0.211; Table 1). No obvious trend could be detected with these
stratified pairwise comparisons.
Assessment of genotyping accuracy
Genotyping accuracy was measured by means of genotype
concordance rate between pairs of sample groups for all 174 SNPs
genotyped (Table 2). The mean genotype concordance rates were
97.9% (SD, 6.9%) between groups 1 and 2 samples, 96.9% (SD,
6.9%) between groups 1 and 3 samples, and 93.6% (SD, 14.5%)
between groups 2 and 3 samples. The overall difference in the
mean genotype concordance rates for all pairs of sample groups
was statistically significant (P=8.47e-9) (Table 2).
For groups 1 and 2, there was neither significant difference in
the mean genotype concordance rate among different multiplex-
ing levels (P=0.491) nor significant correlation between mean
genotype concordance rate and multiplexing level (coefficient = -
0.025, P=0.746; footnote a, Table 2). The same was true for
groups 2 and 3: no significant difference in the mean genotype
concordance rate among different multiplexing levels (P=0.184),
and no significant correlation between mean genotype concor-
dance rate and multiplexing level either (coefficient = -0.008,
P=0.917; footnote c, Table 2). On the other hand, for groups 1
and 3, there was marginally significant difference in the mean
genotype concordance rate among different multiplexing levels
(P=0.050), and significant correlation could be identified
between mean genotype concordance rate and multiplexing level
(coefficient = 0.155, P=0.041; footnote b, Table 2). In addition to
genotype concordance rate, evidence for high degree of genotype
agreement also came from the kappa statistics over the 174 SNPs
(3480 possible genotype pairs): 0.976 for groups 1 and 2, 0.964
for groups 1 and 3, and 0.927 for groups 2 and 3 (details not
shown).
The majority of discordant genotype pairs were due to having
genotype in one sample while having no genotype call in
another of the pair: 62 out of the 72 discordant genotype pairs
between groups 1 and 2, 104 out of 111 discordant genotype
pairs between groups 1 and 3, and 194 out of 223 discordant
genotype pairs between groups 2 and 3. There were more
missing calls for stored wgaDNA (group 3). For discordant
genotype pairs having genotype calls from both samples (i.e. no
missing genotype call), all involved having heterozygous
genotype in one sample (either gDNA or wgaDNA) while
having homozygous genotype in another (either gDNA or
wgaDNA). These included 10 out of 72 discordant genotype
pairs between groups 1 and 2, 7 out of 111 discordant pairs
between groups 1 and 3, and 29 out of 223 discordant pairs
between groups 2 and 3. However, no special pattern could be
detected because equal numbers of heterozygous-to-homozy-
gous or homozygous-to-heterozygous genotype discrepancies
were observed. In addition, variables such as the type of
polymorphisms (A/C, A/G, A/T, C/G, C/T or G/T), the GC
content of PCR products, the extension primer and the length of
PCR products were also examined, but found to have no
correlation with the genotype concordance rate.
Table 2. Summary of genotyping accuracy among sample groups stratified by multiplexing level.
Mean genotype concordance rate
(SD) between groups a & b
P value for pairwise comparison of mean genotype
concordance rates [(Groups a & b) vs (Groups c & d)]e
Multiplexing level No. of SNPs 1 & 2a 1 & 3b 2 & 3c P valued (1 & 2) vs (1 & 3) (1 & 2) vs (2 & 3) (1 & 3) vs (2 & 3)
All 174 97.9 (6.9) 96.9 (6.9) 93.6 (14.5) 8.47e-09 0.039 5.81e-08 2.84e-06
17-plex 17 99.1 (2.0) 92.9 (9.2) 91.5 (11.4) 0.002 0.011 0.007 0.726
21-plex 21 97.6 (6.3) 95.5 (11.8) 93.8 (16.5) 0.42 0.378 0.523 0.614
28-plex 28 95.4 (15.0) 98.0 (3.9) 96.4 (5.1) 0.076 0.805 0.238 0.020
36-plex 108 98.4 (3.0) 97.5 (5.5) 93.1 (16.2) 3.18e-07 0.274 7.75e-07 9.14e-06
aMean genotype concordance rates was not significantly different (P= 0.491, Kruskal-Wallis test) across multiplexing levels. In addition, there was no significant
correlation between mean genotype concordance rates and multiplexing levels (coefficient = -0.025, P= 0.746).
bMean genotype concordance rates was marginally different (P= 0.050, Kruskal-Wallis test) across multiplexing levels. In addition, there was significant correlation
between mean genotype concordance rates and multiplexing levels (coefficient = 0.155, P=0.041).
cMean genotype concordance rates was not significantly different (P=0.184, Kruskal-Wallis test) across multiplexing levels. In addition, there was no significant
correlation between mean genotype concordance rates and multiplexing levels (coefficient = -0.008, P= 0.917).
dP values for comparison of mean genotype concordance rates by Friedman test.
eP values for matched pairwise comparison of mean genotype concordance rates by Wilcoxon signed rank test.
doi:10.1371/journal.pone.0026119.t002
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Correlation between genotyping efficiency and accuracy
For groups 1 and 2 samples, their genotype completion rates were
correlated with the genotype concordance rate between them:
coefficient = 0.375, P=3.36e-7 for group 1 samples; and coeffi-
cient = 0.303, P=4.83e-5 for group 2 samples (Table 3). In other
words, significant and positive correlation could be detected with
both sample groups, and this probably indicated that better
genotyping efficiency led to better genotyping accuracy. Similarly,
for groups 1 and 3 samples, significant correlation could also be
found between their genotype completion rates and the genotype
concordance rate between them (coefficient = 0.323, P=1.34e-5
for group 1 samples; and coefficient = 0.588, P=1.47e-17 for
group 3 samples; Table 3). For groups 2 and 3 samples, the
correlation between their genotype completion rates and the
genotype concordance rate between them was even stronger and
more significant: coefficient = 0.349, P=2.28e-6 for group 2
samples; and coefficient = 0.624, P=3.59e-20 for group 3 samples
(Table 3). This overall correlation also generally matched the
stratified correlation except at certain multiplexing levels (Table 3).
Stratified analysis indicated that this correlation was more
consistently detected, but not necessarily stronger in magnitude,
at higher level of multiplexing than lower level of multiplexing: 6
out of 6 scenarios for 36-plex assays, but only 2 out of 6 scenarios
for 17-plex assay. This could probably be explained by the
relatively smaller sample size for the 17-plex level with only 17
SNPs when compared with 108 SNPs for the 36-plex level.
Discussion
Consistent with previous studies, the present study showed that
wgaDNAs (freshly prepared or stored at 270uC for 18 months)
had satisfactory genotyping efficiency collectively and at various
multiplexing levels (Table 1). In addition, the high concordance of
genotypes between group 1 (gDNA) and group 2 (fresh wgaDNA)
samples as well as between group 1 (gDNA) and group 3 (stored
wgaDNA) samples indicated the high genotyping accuracy of
wgaDNA (Table 2). This further testified the validity of using
wgaDNA as a replacement for gDNA. More importantly, together
with the findings from other wgaDNA studies, the present study
highlighted the great scalability of our existing limited gDNA
assets. In other words, the application of WGA on gDNA expands
the amount of our valuable DNA samples such that they can last
for more experiments. Since the WGA process can normally
amplify DNA by .1000-fold, it is anticipated that the samples can
last for substantially greater number of use.
The validity of wgaDNA for ordinary use has been well justified
[7,14] and wgaDNA has previously been tested on medium-
throughput MassARRAY platform with iPLEX GOLD chemistry
[17]. However, to our knowledge, this study is the first one that
made use of the variable multiplexing ability of the same
genotyping technology to study the relationship between genotyp-
ing performance and multiplexing level of the assays using
wgaDNA, and to examine whether the storage of wgaDNA would
reduce the genotyping efficiency. Indeed, existing studies [15,19–
22] have successfully addressed the question of whether wgaDNA
could be used in high-throughput array-based assays, e.g.,
Affymetrix and Illumina genotyping chips. High concordance
was detected between wgaDNA and gDNA, highlighting the
reliability of using wgaDNA for high-throughput genotyping with
good accuracy. Nonetheless, different assays have different
reaction chemistries. Such successful application of wgaDNA in
high-throughput array-based assays does not necessarily imply that
genotyping performance would not deteriorate with increasing
multiplexing level of the assays upon the use of wgaDNA. While
high-throughput array-based assays use either uniform or random
primers for template amplification, MassARRAY assays employ a
different technology that requires multiple sets of specific primers
to amplify multiple specific regions. Such specificity requirement
becomes even more critical with increasing level of multiplexing in
the MassARRAY assays. From this perspective, results from
previous studies of high-throughput array-based assays [15,16] or
even the MassARRAY-based study of a single multiplex group of
35-plex by Hollegaard et al. [17] could not be extrapolated
directly to provide the necessary information on the issues
addressed by our current study. This was the reason why our
current study was carried out.
In our study, data were stratified according to sample group and
multiplexing level. Analysis of the mean genotype completion
rates among the 3 sample groups detected statistically significant
difference (P=0.002) (Table 1), suggesting that there was a marked
difference. Indeed, by pairwise comparison of mean genotype
completion rates (Table 1), groups 1 and 3 samples were found to
show the most remarkable difference in genotyping efficiencies
(P=1.73e-4; group 3 being lower than group 1, 93.0% vs 96.8%).
Similarly, difference was also found between genotyping efficien-
cies of groups 2 and 3 samples (P=0.003; group 3 being lower
than group 2, 93.0% vs 96.2%). This evidence suggested the
inferior quality of group 3 samples because group 2 (freshly
prepared wgaDNA) samples were found to have similar genotyp-
ing efficiency as group 1 (gDNA) samples.
Table 3. Summary of correlation between genotyping efficiency and accuracy among groups 1, 2 and 3 samples stratified by
multiplexing level.
Correlation between completion
rate and concordance rate for
genotypes (groups 1 vs 2)
Correlation between completion
rate and concordance rate for
genotypes (groups 1 vs 3)
Correlation between completion
rate and concordance rate for
genotypes (groups 2 vs 3)
Multiplexing level No. of SNPs Group 1 Group 2 Group 1 Group 3 Group 2 Group 3
All 174 0.375
(P=3.36e-7)
0.303
(P=4.83e-5)
0.323
(P=1.34e-5)
0.588
(P=1.47e-17)
0.349
(P=2.28e-6)
0.624
(P=3.59e-20)
17-plex 17 0.190 (P= 0.464) -0.169 (P= 0.517) 0.140 (P=0.592) 0.884 (P=2.54e-6) -0.097 (P=0.710) 0.838 (P=2.70e-5)
21-plex 21 0.638 (P=0.002) 0.471 (P=0.031) 0.536 (P=0.012) 0.073 (P= 0.755) 0.142 (P= 0.540) 0.583 (P=0.006)
28-plex 28 0.342 (P= 0.075) 0.431 (P=0.022) 0.205 (P=0.296) 0.789 (P=5.97e-7) 0.683 (P=6.18e-5) 0.666 (P=1.08e-4)
36-plex 108 0.359
(P=1.35e-4)
0.275
(P=0.004)
0.329
(P=0.001)
0.561
(P=2.59e-10)
0.392
(P=2.77e-5)
0.556
(P=4.07e-10)
doi:10.1371/journal.pone.0026119.t003
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Moreover, mean genotype completion rates of SNPs were
compared across different multiplexing levels (Table 1). Although
the mean genotype completion rates seemed to be different among
the groups by visual inspection, the difference was not statistically
significant in any sample group because of the high variance of
genotype completion rates (footnotes a to c, Table 1). However,
significant correlation, despite quite weak, could be detected between
genotype completion rates and multiplexing levels in sample
groups 1 and 2 (footnotes a and b, Table 1). This suggested that
genotype completion rate decreased monotonically with increasing
multiplexing level in these 3 groups of samples. It is intuitive to
think that the complexity of the assay increases with increasing
level of multiplexing, and this poses greater difficulty to the assay
and adversely affects the genotyping efficiency. That the
correlation was weak could probably reflect the effectiveness of
the primer design algorithm used by the Sequenom assays for
multiplex PCR. Multiplexing that has a high chance of failure
might have been removed beforehand. Other factors like the type
of genetic polymorphisms tested also influence the overall
complexity of the assay. This phenomenon seemed to be valid in
sample groups 1 and 2, but not 3. Group 3 samples were stored
wgaDNAs that had been kept at 270uC for 18 months.
Our result showed that the overall genotype completion rate of
group 3 samples (93.0%) was the lowest among the 3 sample
groups (Table 1). Given that groups 2 (freshly prepared wgaDNA)
and 3 (stored wgaDNA) samples were both originated from the
same WGA reactions (2 sets of aliquots of the same WGA products
and immediately frozen at 270uC after completing the WGA), the
major difference between them was the storage period. Group 3
samples had been stored for 18 months while group 2 samples
were used for genotyping within one week after WGA. The quality
of group 3 samples could be inferior to that of the others such that
the potential correlation between genotyping efficiency and
multiplexing level could not be observed (footnote c, Table 1).
Our data suggested that, with gDNAs as the reference, the
correlation was not disrupted or exaggerated by the use of freshly
prepared wgaDNA samples, which were believed to have better
quality than stored wgaDNA samples. This indicated that the use
of freshly prepared wgaDNA would not incur additional adverse
burden although increasing multiplexing level was suggested to
lead to slight deterioration in genotyping efficiency.
On the other hand, concerning genotyping accuracy, high
concordance of genotypes could be observed between groups 1
and 2, groups 1 and 3 as well as groups 2 and 3 samples in terms of
genotype concordance rate (Table 2) and kappa statistic (details
not shown). Nonetheless, significant difference could be detected
among the mean genotype concordance rates (P=8.47e-9,
Table 2) with that between groups 2 and 3 samples being the
lowest (93.6%). As a result, the use of stored wgaDNA was likely to
reduce the genotyping accuracy of MassARRAY assays. If group 1
gDNA samples are treated as the reference, the mean genotype
concordance rates with group 1 samples will reflect the variability
or uncertainty in genotype accuracy – the lower the genotype
concordance rate, the more uncertain it is for the genotyping
results. Indeed, the degree of uncertainty was significantly higher
for group 3 samples. As there were some discrepancies between
groups 1 and 2 samples, it was reasonable to believe that even
freshly prepared wgaDNA samples could introduce some degree of
uncertainty to the genotyping results due to the WGA process.
More importantly, the mean genotype concordance rate was even
worse between groups 1 and 3 samples. This indicated that 18-
month storage of wgaDNA samples even at 270uC further
deteriorated the situation by introducing additional uncertainty to
the genotyping results. Therefore, the concordance was the lowest
(93.6%, Table 2) between group 2 (with uncertainty from WGA
process) and group 3 (with uncertainties from both the WGA
process and the storage period) samples. Taken together, our
results showed that the genotyping performance of freshly
prepared wgaDNA, but not stored wgaDNA, was similar to that
of gDNA. Therefore, this evidence highlighted the importance of
using fresh wgaDNA samples in order to obtain better genotyping
performance for MassARRAY assays.
Since MassARRAY assay is a popular medium-throughput
genotyping platform for following up a moderate number of SNP
markers, researchers might enjoy the high scalability of existing
DNA samples by using WGA on one hand, and relieve their
worries about potential burden of wgaDNA on variable multi-
plexing assay on the other hand. As stored wgaDNAs were
suggested to have inferior genotyping efficiency and accuracy,
further study is warranted to investigate whether stored wgaDNAs
would have lower genotyping performance in other genotyping
platforms.
There were limitations in our current study. First, the scale of
our study is relatively small with only 60 matched samples (20
gDNA, 20 freshly prepared wgaDNA and 20 stored wgaDNA).
Second, our current study has not yet addressed in depth the effect
of long-term storage on the quality of wgaDNA samples because
group 3 (stored wgaDNA) samples have only been stored for 18
months before use. Third, our current study did not include a
clean-up step after WGA.
Given our experience to date with wgaDNA stored frozen at
270uC for up to 18 months, further study of a larger sample set
stored for even longer periods (at least 2–5 years or longer) would
be warranted to confirm our initial findings of its deleterious effects
on genotyping efficiency and accuracy. Based on our results of
reduced genotyping performance with increasing storage time,
especially in terms of accuracy, caution is indicated for genotyping
data of wgaDNA samples. Cautious handling of wgaDNA is also
important. First, it is necessary to have better planning for
experiments so as to minimize the storage period for wgaDNA.
Second, making reasonable aliquots of wgaDNA samples can
effectively reduce the number of freezing-thawing cycles, which is
believed to seriously influence the quality of all DNA samples
including wgaDNA. Third, WGA products should be purified and
kept in TE buffer instead of water. It is of particular concern that
Mg2+ ion is present in the WGA reaction buffer and is required for
the enzymatic activity of the Q29 DNA polymerase used in MDA.
This metal ion is also the co-factor for DNase, an enzyme
degrading DNA. It may thus be a good idea to remove it by
purification after WGA. It might also be good to report the storage
period for wgaDNA in publications because variation of
genotyping efficiency in different studies could be due to different
storage periods of wgaDNA samples.
Last but not least, our results suggested that the higher the
genotyping efficiency, the better the genotyping accuracy was
(Table 3). This relationship was valid for all gDNA, freshly
prepared wgaDNA and stored wgaDNA. This suggests that
MassARRAY assay is reliable for all kinds of samples when the
genotyping efficiency (i.e. genotype completion rate) is high.
In summary, significant, though weak, correlation between
genotyping efficiency and multiplexing level was detected in both
gDNA and freshly prepared wgaDNA. Since the degree of
correlation was similar for both sample groups, this indicated the
absence of additional adverse effect of using freshly prepared
wgaDNA on genotyping efficiency of MassARRAY assay although
increasing multiplexing level tended to lead to modest deteriora-
tion in genotyping efficiency in general. Moreover, the genotyping
performance of freshly prepared wgaDNAs was found to be
wgaDNA - Genotyping Performance in MassARRAY Assay
PLoS ONE | www.plosone.org 5 October 2011 | Volume 6 | Issue 10 | e26119
similar to that of gDNA collectively and with respect to various
multiplexing levels. However, stored wgaDNA gave lower
genotyping efficiency and accuracy than gDNA and freshly
prepared wgaDNA due to potentially inferior quality. Finally,
there was a significant correlation between genotyping efficiency
and genotyping accuracy. Therefore, MassARRAY assay is
reliable when genotyping efficiency is satisfactory.
Materials and Methods
DNA Samples
For the purpose of performance comparison, three groups of
matched DNA samples were used in this study: 20 gDNA samples
extracted from whole blood (group 1), 20 wgaDNA samples freshly
amplified from the corresponding ‘‘group 1’’ gDNA (group 2) and
20 wgaDNA samples amplified from the corresponding "group 1"
gDNA and stored frozen at 270uC for 18 months (group 3).
Group 2 and 3 samples were aliquots of the same WGA products,
which were prepared using GenomiPhi V2 DNA Amplification
Kit (GE Healthcare Life Sciences) according to the manufacturer’s
instructions, and used for genotyping without further purification.
Group 2 samples were freshly prepared and used for genotyping
within one week after WGA. Group 3 samples had been stored at
270uC for 18 months prior to the genotyping process. Both
groups of wgaDNA samples were immediately frozen after the
WGA process, and thawed before use to avoid repeated freezing-
thawing cycles. Informed consent was obtained from all subjects.
Ethical approval for the study was obtained from the Human
Subjects Ethics Subcommittee of the Hong Kong Polytechnic
University, and adhered to the tenets of the Declaration of
Helsinki.
SNP genotyping
Genotyping of 174 SNPs was done at the Genome Research
Centre, the University of Hong Kong, as a contract service using
the Sequenom MassARRAY technology platform with the iPLEX
GOLD chemistry (Sequenom, San Diego, CA). The manufactur-
er’s protocols were followed closely. Briefly, specific assays were
designed using MassARRAY AssayDesign software package (v3.1)
with filtering of proximal SNPs and checking of specificity for PCR
amplification and the subsequent primer extension reaction. One
ml of DNA sample (15 ng/ml) was used in each PCR. Residual
nucleotides were dephosphorylated before the iPLEX GOLD
reaction. After single-base extension, reaction products were
desalted with SpectroCLEAN resin (Sequenom, San Diego, CA),
and an aliquot of 10 nL of the desalted product was spotted onto a
384-format SpectroCHIP with the MassARRAY Nanodispenser.
Mass determination was done with the MassARRAY Analyzer
Compact MALDI-TOF mass spectrometer. The MassARRAY
Typer 4.0 software was used for data acquisition and analysis.
Genotypes were called after cluster analysis using the default
setting of Gaussian mixture model. Genotype calls were then
further reviewed manually to undo any uncertain calls due to
clustering artifact. Assay with less than 80% call rate within the
same SpectroCHIP was considered failed. For every 96-well
sample plate, one well was used for blank control and five wells for
duplicate check. SpectroCHIP with more than 25% call rate in the
blank control was considered failed and would be repeated.
SpectroCHIP with less than 99.5% concordance in duplicate
checks along with more than 10% call rate in blank check was also
considered failed.
Statistical Analysis
To measure genotyping efficiency, means and variances of
genotype completion rates (percentage of successful genotype calls,
i.e. proportion of samples that could be genotyped successfully
with respect to an individual SNP as well as overall dataset) were
compared among 3 groups of samples by nonparametric Wilcoxon
signed rank test, Friedman test and Kruskal-Wallis test as
appropriate. Genotyping accuracy was evaluated by pairwise
comparison of actual genotypes between matched sample pairs
(groups 1 and 2, groups 1 and 3 as well as groups 2 and 3), and
agreement was summarized in terms of genotype concordance rate
(percentage of identical genotype calls) and kappa statistic. Data
were stratified by multiplexing level in MassARRAY assay with
groups of SNPs multiplexed in 17-plex (17 SNPs), 21-plex (21
SNPs), 28-plex (28 SNPs) and 36-plex (3 sets; 108 SNPs in total).
Nonparametric Spearman correlation was used to detect correla-
tion between variables. Analysis was done with SPSS (ver. 16.0,
Chicago, IL) and Excel.
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